Fabian Bernhard Thaddaeus Kraus, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Histamine | 1 | 2022 | 23 | 0.830 |
Why?
|
| Vulvar Neoplasms | 1 | 2024 | 263 | 0.760 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 533 | 0.630 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 4878 | 0.570 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 1607 | 0.400 |
Why?
|
| Biological Specimen Banks | 2 | 2024 | 784 | 0.300 |
Why?
|
| Adoptive Transfer | 2 | 2018 | 822 | 0.230 |
Why?
|
| 20-Hydroxysteroid Dehydrogenases | 1 | 2022 | 6 | 0.210 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2023 | 129 | 0.210 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2022 | 29 | 0.200 |
Why?
|
| Cyproheptadine | 1 | 2021 | 19 | 0.200 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2022 | 155 | 0.190 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2021 | 285 | 0.180 |
Why?
|
| Carboplatin | 1 | 2022 | 789 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2023 | 1245 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 1147 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2023 | 2210 | 0.120 |
Why?
|
| Ovalbumin | 1 | 2015 | 674 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2022 | 1529 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2018 | 4550 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 1229 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2022 | 1357 | 0.110 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 975 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 3725 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 1378 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 3734 | 0.090 |
Why?
|
| Prognosis | 4 | 2023 | 29661 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5349 | 0.080 |
Why?
|
| Organoids | 2 | 2024 | 729 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3157 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 16932 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2018 | 897 | 0.060 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2023 | 33 | 0.050 |
Why?
|
| Histological Techniques | 1 | 2023 | 194 | 0.050 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2022 | 8 | 0.050 |
Why?
|
| Female | 9 | 2024 | 391246 | 0.050 |
Why?
|
| Peptide Elongation Factors | 1 | 2022 | 62 | 0.050 |
Why?
|
| Co-Repressor Proteins | 1 | 2023 | 191 | 0.050 |
Why?
|
| Platelet Activating Factor | 1 | 2021 | 143 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11713 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 376 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2023 | 1089 | 0.040 |
Why?
|
| beta Catenin | 1 | 2023 | 1043 | 0.040 |
Why?
|
| Humans | 9 | 2024 | 760613 | 0.040 |
Why?
|
| Ovary | 1 | 2021 | 958 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 21029 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2024 | 80345 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 9530 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 780 | 0.030 |
Why?
|
| Cell Survival | 1 | 2022 | 5797 | 0.020 |
Why?
|
| Epitopes | 1 | 2015 | 2503 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 11152 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 5251 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10442 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2021 | 23374 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2021 | 64981 | 0.010 |
Why?
|
| Mice | 2 | 2018 | 81209 | 0.010 |
Why?
|
| Middle Aged | 2 | 2022 | 220359 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 167960 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 169143 | 0.000 |
Why?
|